Financial News

vTv Therapeutics Out-licenses COPD Treatment to China's Newsoara

vTv Therapeutics of North Carolina out-licensed China and Pacific Rim rights for a clinical-stage treatment aimed at inflammatory conditions to China's Newsoara Biopharma. HPP737, a PDE4 Inhibitor, is expected to treat COPD and other inflammatory diseases. Newsoara will make an upfront payment along with development and commercialization milestones, plus royalties on sales. Based on Phase I trials, vTV believes HPP737 will be better tolerated than currently available PDE4 inhibitors. More details.... Stock Symbol: (NSDQ: VTVT) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback